These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 32294439)
1. Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities. Dinh TA; Sritharan R; Smith FD; Francisco AB; Ma RK; Bunaciu RP; Kanke M; Danko CG; Massa AP; Scott JD; Sethupathy P Cell Rep; 2020 Apr; 31(2):107509. PubMed ID: 32294439 [TBL] [Abstract][Full Text] [Related]
4. Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma. Francisco AB; Kanke M; Massa AP; Dinh TA; Sritharan R; Vakili K; Bardeesy N; Sethupathy P JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35482409 [TBL] [Abstract][Full Text] [Related]
5. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma. Gulati R; Johnston M; Rivas M; Cast A; Kumbaji M; Hanlon MA; Lee S; Zhou P; Lake C; Schepers E; Min KW; Yoon JH; Karns R; Reid LM; Lopez-Terrada D; Timchenko L; Parameswaran S; Weirauch MT; Ranganathan S; Bondoc A; Geller J; Tiao G; Shin S; Timchenko N Hepatol Commun; 2022 Oct; 6(10):2950-2963. PubMed ID: 36000549 [TBL] [Abstract][Full Text] [Related]
6. Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. Malouf GG; Tahara T; Paradis V; Fabre M; Guettier C; Yamazaki J; Long H; Lu Y; Raynal NJ; Jelinek J; Mouawad R; Khayat D; Brugières L; Raymond E; Issa JP Epigenetics; 2015; 10(9):872-81. PubMed ID: 26224146 [TBL] [Abstract][Full Text] [Related]
7. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Kannangai R; Vivekanandan P; Martinez-Murillo F; Choti M; Torbenson M Hum Pathol; 2007 Apr; 38(4):639-44. PubMed ID: 17367606 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. Dinh TA; Vitucci EC; Wauthier E; Graham RP; Pitman WA; Oikawa T; Chen M; Silva GO; Greene KG; Torbenson MS; Reid LM; Sethupathy P Sci Rep; 2017 Mar; 7():44653. PubMed ID: 28304380 [TBL] [Abstract][Full Text] [Related]
9. Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer. Okabe A; Kaneda A Cancer Sci; 2021 Jun; 112(6):2081-2088. PubMed ID: 33728716 [TBL] [Abstract][Full Text] [Related]
10. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma. Jewell ML; Gibson JR; Guy CD; Hyun J; Du K; Oh SH; Premont RT; Hsu DS; Ribar T; Gregory SG; Diehl AME Am J Pathol; 2020 Jan; 190(1):93-107. PubMed ID: 31669305 [TBL] [Abstract][Full Text] [Related]
11. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways. Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922 [TBL] [Abstract][Full Text] [Related]
12. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328 [TBL] [Abstract][Full Text] [Related]
13. LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway. Zhang Q; Cheng S; Cao L; Yang J; Wang Y; Chen Y Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32077915 [TBL] [Abstract][Full Text] [Related]
14. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data. Kim J; Kim Y; Lee B Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849 [TBL] [Abstract][Full Text] [Related]
15. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma. Ribback S; Che L; Pilo MG; Cigliano A; Latte G; Pes GM; Porcu A; Pascale RM; Li L; Qiao Y; Dombrowski F; Chen X; Calvisi DF Cell Cycle; 2018; 17(12):1496-1512. PubMed ID: 29965794 [TBL] [Abstract][Full Text] [Related]
16. An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma. Turnham RE; Smith FD; Kenerson HL; Omar MH; Golkowski M; Garcia I; Bauer R; Lau HT; Sullivan KM; Langeberg LK; Ong SE; Riehle KJ; Yeung RS; Scott JD Elife; 2019 May; 8():. PubMed ID: 31063128 [TBL] [Abstract][Full Text] [Related]
17. Genome-wide DNA methylation and hydroxymethylation analysis reveal human menstrual blood-derived stem cells inhibit hepatocellular carcinoma growth through oncogenic pathway suppression via regulating 5-hmC in enhancer elements. Wu Y; Chen X; Zhao Y; Wang Y; Li Y; Xiang C Stem Cell Res Ther; 2019 May; 10(1):151. PubMed ID: 31151404 [TBL] [Abstract][Full Text] [Related]
18. Phase Separation of a PKA Regulatory Subunit Controls cAMP Compartmentation and Oncogenic Signaling. Zhang JZ; Lu TW; Stolerman LM; Tenner B; Yang JR; Zhang JF; Falcke M; Rangamani P; Taylor SS; Mehta S; Zhang J Cell; 2020 Sep; 182(6):1531-1544.e15. PubMed ID: 32846158 [TBL] [Abstract][Full Text] [Related]
19. Targeting of noncoding RNAs encoded by a novel MYC enhancers inhibits the proliferation of human hepatic carcinoma cells in vitro. Choi HI; An GY; Yoo E; Baek M; Chai JC; Binas B; Lee YS; Jung KH; Chai YG Sci Rep; 2022 Jan; 12(1):855. PubMed ID: 35039581 [TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway. Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318 [No Abstract] [Full Text] [Related] [Next] [New Search]